[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
..
Publication Charge
►Publication Fee
..
In Press
 In Press Articles
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 13, Issue 2 (Spring 2022) ::
Caspian J Intern Med 2022, 13(2): 349-355 Back to browse issues page
Recover burn ointment for managing acute radiodermatitis in patients with breast cancer: A double blind randomized controlled trial
Nargeuss Abbaszade Marzbali , Ebrahim Zabihi , Nicolas Magne , Alexis Vallard , Mohammad Moslemi , Dariush Moslemi
Babol University of Medical Sciences , moslemi_d@yahoo.com
Abstract:   (2596 Views)
Background: Radiodermatitis is the most common complication of radiotherapy. There is no gold standard for managing the radiodermatitis. This study aimed to evaluate the effect of topical Recove® burn ointment; basically compounded of sesame oil, camphor, and zinc oxide; in preventing acute radiodermatitis.
Methods: This double blind RCT (IRCT No.: 201204047136N2) was performed on 71 patients that referred for radiotherapy after mastectomy to Shahid Rajaee Hospital (Babolsar-Iran) during 2013-2017. Patients were allocated into 2 groups; 34 in control group and 37 in Recove® group. Patients applied the ointment 2 times a day, before every radiation therapy session for 5 weeks. The radiation oncologist assessed the severity of dermatitis weekly for 5 weeks and graded it from 0 to 4 according to the RTOG criteria.
Results:Baseline characteristics including age, and BMI had no significant difference between groups. The Recover group patients experienced significantly less severe dermatitis compared to the controls (p<0.001). None of the patients in Recove® group encountered more than grade 2 of RTOG criteria, however, in the control group, 4 (12.9%)patients experienced grade 3 of RTOG and 3 (9.7%)patients developed grade 4 of RTOG at the end of the 5th week.
Conclusion: Our results indicate that Recove® ointment significantly reduces the severity of acute radiodermatitis.
Keywords: breast cancer, radiotherapy, radiodermatitis, Recove ointment, radiation therapy oncology group.
Full-Text [PDF 207 kb]   (562 Downloads)    
Type of Study: Original Article | Subject: Oncology
Received: 2020/10/29 | Accepted: 2021/08/22 | Published: 2022/02/21
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbaszade Marzbali N, Zabihi E, Magne N, Vallard A, Moslemi M, Moslemi D. Recover burn ointment for managing acute radiodermatitis in patients with breast cancer: A double blind randomized controlled trial. Caspian J Intern Med 2022; 13 (2) :349-355
URL: http://caspjim.com/article-1-2568-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 2 (Spring 2022) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.07 seconds with 40 queries by YEKTAWEB 4645